US SEC Trading Suspension Halt Orders — June 16, 2026

Regained Nasdaq compliance after 10 consecutive days above $1.00, removing delisting risk

Compliance notice received June 10, 2026, confirming bid price rule satisfaction

Stock traded on Nasdaq Global Select Market (MXCT) with improved liquidity outlook

No further regulatory halts or suspensions expected from this matter

Stock previously at risk of delisting; any future dip below $1.00 could trigger another compliance process

Low-priced stocks remain vulnerable to volatility and potential non-compliance

Thin trading volumes could exacerbate price swings

Absence of insider buying post-compliance may indicate lack of management confidence

Lack of revenue or earnings outlook limits visibility on fundamentals

Removal of delisting overhang could attract new investors and improve sentiment

Stock may see upward re-rating as regulatory risk dissipates

Biotech sector often rewards compliance resolutions with positive momentum

Single filing shows isolated compliance resolution; no broader trend in trading suspensions or halts

Companies near $1.00 face recurring compliance challenges; monitoring required

Monitor stock price stability above $1.00; any sustained decline could trigger new compliance notice

Upcoming earnings report for forward guidance and financial health update

Insider trading activity post-compliance for management sentiment signal